Research News

New drugs that block brain peptide reduce migraine attacks, trials show

BMJ 2017; 359 doi: (Published 30 November 2017) Cite this as: BMJ 2017;359:j5596
  1. Susan Mayor
  1. London

A new monoclonal antibody that inhibits the calcitonin gene related peptide (CGRP) receptor, which plays a central role in the pathophysiology of migraine, significantly reduced the frequency of migraine episodes in the first phase 3 randomised trial to investigate erenumab in preventing episodic migraine.1 Another new agent blocking the same peptide, fremanezumab, also reduced the frequency of headache in patients with chronic migraine in a second trial.2

“Erenumab administered subcutaneously significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine specific drugs over a period of six months,” said the authors of the episodic migraine trial, led by Peter Goadsby from King’s College Hospital, London, UK. They added, “The treatment response achieved with erenumab was apparent from the first efficacy time point at one month, which suggests that patients had an early benefit.” They said that further trials are needed …

View Full Text

Log in

Log in through your institution


* For online subscription